In conclusion, we demonstrated that the CSD peptide LTI-2355 enhances the phagocytic activity and modulates the synthetic activity of IPF and PASC-F myeloid cells in a CD206-dependent manner, indicating a novel mechanism of action, by which CSD peptides may confer therapeutic benefits. Here, MRC1 is linked to idiopathic pulmonary fibrosis.